Örjan Friberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Örjan Friberg has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Anders Holmgren
Department of Public Health and Clinical Medicine, Umeå University , Umeå
3 shared publications - Bo Söderquist
School of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro
3 shared publications - Farkas Vánky
Department of Health, Medicine and Caring Sciences, Unit of Cardiovascular Medicine, Linköping University, Linköping, Sweden
3 shared publications - Rolf Svedjeholm
Department of Health, Medicine and Caring Sciences, Unit of Cardiovascular Medicine, Linköping University, Linköping, Sweden
3 shared publications - Anders Jeppsson
Sahlgrenska University Hospital
2 shared publications - Ann-Sofie Sundqvist
School of Health Sciences, Faculty of Medicine and Health, Örebro University, Sweden
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in JTCVS Open
Long-term risk of dementia after open thoracic aortic surgery: A population-based cohort study
- 29 September 2026
- Published by Elsevier in JTCVS Open
Open AccessLong-term risk of dementia after open thoracic aortic surgery: A population-based cohort study
- Open Access
- 10 September 2026
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 60 (1)
Risk factors for leg wound infection after conventional and no-touch vein harvesting: insights from a multicentre randomised trial
Coronary artery bypass grafting (CABG) is the recommended treatment for patients with advanced multi-vessel coronary artery disease [1]. Although the use of the left internal mammary artery is well...
- 10 September 2026
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 60 (1)
Open AccessRisk factors for leg wound infection after conventional and no-touch vein harvesting: insights from a multicentre randomised trial
Coronary artery bypass grafting (CABG) is the recommended treatment for patients with advanced multi-vessel coronary artery disease [1]. Although the use of the left internal mammary artery is well...
- Open Access
- 9 March 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (4)
Refitting EuroSCORE II for 120-Day Mortality After Coronary Artery Bypass Grafting Using Nationwide Registry Data
Objectives: The EuroSCORE II risk prediction model is the current gold standard in Europe to predict in-hospital mortality after cardiac surgery and is widely used in clinical decision-making and outcome reporting. A risk prediction model specifically for patients undergoing elective or urgent isolated coronary artery bypass grafting (CABG), a commonly performed cardiac procedure, may lead to a better performance for individual risk prediction. The aim of this study is to validate and refit the EuroSCORE II for 120-day mortality, using international multicentre data from 2 national quality registries. Methods: All elective or urgent isolated CABG procedures performed between 2013 and 2019 in adult patients were included using nationwide data from the Netherlands Heart Registration and SWEDEHEART. The performance of the EuroSCORE II was analysed in the Dutch cohort and refitted by estimating a new intercept and coefficient for the linear predictor of the original EuroSCORE II. This refitted model was validated in the Swedish cohort and tested against the original EuroSCORE II model. Results: In total 45 016 procedures from the Netherlands were included for validation and refitting of the model. The refitted model showed similar discrimination to the EuroSCORE II and could be marginally optimized by adding the interaction between age and sex, resulting in a C-statistic of 0.80. This refitted model was validated using 16 374 procedures from the Swedish cohort. The refitted model showed improved calibration and discrimination compared to the original EuroSCOREII. Conclusions: We present a refitted risk prediction model for 120-day mortality after elective or urgent isolated CABG using high-quality nationwide data.
- 9 March 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (4)
Open AccessRefitting EuroSCORE II for 120-Day Mortality After Coronary Artery Bypass Grafting Using Nationwide Registry Data
Objectives: The EuroSCORE II risk prediction model is the current gold standard in Europe to predict in-hospital mortality after cardiac surgery and is widely used in clinical decision-making and outcome reporting. A risk prediction model specifically for patients undergoing elective or urgent isolated coronary artery bypass grafting (CABG), a commonly performed cardiac procedure, may lead to a better performance for individual risk prediction. The aim of this study is to validate and refit the EuroSCORE II for 120-day mortality, using international multicentre data from 2 national quality registries. Methods: All elective or urgent isolated CABG procedures performed between 2013 and 2019 in adult patients were included using nationwide data from the Netherlands Heart Registration and SWEDEHEART. The performance of the EuroSCORE II was analysed in the Dutch cohort and refitted by estimating a new intercept and coefficient for the linear predictor of the original EuroSCORE II. This refitted model was validated in the Swedish cohort and tested against the original EuroSCORE II model. Results: In total 45 016 procedures from the Netherlands were included for validation and refitting of the model. The refitted model showed similar discrimination to the EuroSCORE II and could be marginally optimized by adding the interaction between age and sex, resulting in a C-statistic of 0.80. This refitted model was validated using 16 374 procedures from the Swedish cohort. The refitted model showed improved calibration and discrimination compared to the original EuroSCOREII. Conclusions: We present a refitted risk prediction model for 120-day mortality after elective or urgent isolated CABG using high-quality nationwide data.
- Open Access
- 29 March 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (4)
High incidence of permanent pacemaker after Cox-maze IV and mitral valve surgery: a nationwide registry-based study
OBJECTIVES: This study evaluated the long-term risk of permanent pacemaker implantation following Cox-maze IV (CMIV) and concurrent mitral valve surgery. METHODS: A retrospective, nationwide, registry-based analysis was conducted on postoperative permanent pacemaker implantation in 397 patients with symptomatic mitral valve insufficiency and atrial fibrillation who underwent CMIV and mitral valve surgery in Sweden between 2009 and 2017. They were compared to a registry group of 346 patients with atrial fibrillation who underwent mitral valve surgery without surgical ablation during 2014–2017. The follow-up ended on 30 September 2022. RESULTS: CMIV patients were on average 4 years younger and had lower surgical risk than registry patients. More CMIV patients underwent early (60% of early pacemaker indications in both groups, and sinus node dysfunction was the indication for late pacemaker implantation in 48% in the CMIV group. CONCLUSIONS: Patients undergoing CMIV concomitant with mitral valve surgery have a higher rate of postoperative pacemaker implantation compared to patients with atrial fibrillation undergoing mitral valve surgery alone. Sinus node dysfunction was the main indication for late pacemaker among CMIV patients.
- 29 March 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (4)
Open AccessHigh incidence of permanent pacemaker after Cox-maze IV and mitral valve surgery: a nationwide registry-based study
OBJECTIVES: This study evaluated the long-term risk of permanent pacemaker implantation following Cox-maze IV (CMIV) and concurrent mitral valve surgery. METHODS: A retrospective, nationwide, registry-based analysis was conducted on postoperative permanent pacemaker implantation in 397 patients with symptomatic mitral valve insufficiency and atrial fibrillation who underwent CMIV and mitral valve surgery in Sweden between 2009 and 2017. They were compared to a registry group of 346 patients with atrial fibrillation who underwent mitral valve surgery without surgical ablation during 2014–2017. The follow-up ended on 30 September 2022. RESULTS: CMIV patients were on average 4 years younger and had lower surgical risk than registry patients. More CMIV patients underwent early (60% of early pacemaker indications in both groups, and sinus node dysfunction was the indication for late pacemaker implantation in 48% in the CMIV group. CONCLUSIONS: Patients undergoing CMIV concomitant with mitral valve surgery have a higher rate of postoperative pacemaker implantation compared to patients with atrial fibrillation undergoing mitral valve surgery alone. Sinus node dysfunction was the main indication for late pacemaker among CMIV patients.
- Open Access
- 19 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (18) , 1720-1729
No-touch vein grafts in coronary artery bypass surgery: a registry-based randomized clinical trial
Background and Aims: No-touch saphenous vein harvesting may enhance graft patency and improve clinical outcomes after coronary artery bypass grafting (CABG). Methods: In this registry-based, randomized trial, patients undergoing CABG were randomly assigned to no-touch or conventional harvesting. The primary composite outcome was the proportion of patients with occluded/stenosed >50% vein graft on coronary computed tomography angiography, or who underwent percutaneous coronary intervention to a vein graft, or died. Secondary outcomes included clinical outcomes and leg wound complications. Results: A total of 902 patients were enrolled with a mean total number of distal vein anastomoses of 2.0 (SD 0.87). The primary endpoint occurred in 90/454 (19.8%) of patients randomized to no-touch and in 107/446 (24.0%) of patients randomized to the conventional technique [difference, −4.3 percentage points; 95% confidence interval (CI) −10.1–1.6; P = .15] at a mean follow-up time of 3.5 (SD 0.1) years. The composite of death, myocardial infarction, or repeat revascularization at 4.4 (SD 1.3) years occurred in 57/454 (12.6%) and 44/446 (9.9%) in the no-touch and conventional groups, respectively (hazard ratio 1.3; 95% CI, 0.87–1.93). Leg wound complications were more common in patients assigned to no-touch harvesting at 3 months [107/433 (24.7%) vs. 59/427 (13.8%); difference, 10.9 percentage points; 95% CI 5.7–16.1]. At 2 years, 189/381 (49.6%) vs. 91/361 (25.2%) had remaining leg symptoms (difference, 24.4 percentage points; 95% CI 17.7–31.1). Conclusions: No-touch vein graft harvesting for CABG was not superior to conventional open harvesting in reducing vein graft failure or clinical events after CABG but increased leg wound complications. The primary outcome requires cautious interpretation due to a lower-than-expected number of primary events.
- 19 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (18) , 1720-1729
Open AccessNo-touch vein grafts in coronary artery bypass surgery: a registry-based randomized clinical trial
Background and Aims: No-touch saphenous vein harvesting may enhance graft patency and improve clinical outcomes after coronary artery bypass grafting (CABG). Methods: In this registry-based, randomized trial, patients undergoing CABG were randomly assigned to no-touch or conventional harvesting. The primary composite outcome was the proportion of patients with occluded/stenosed >50% vein graft on coronary computed tomography angiography, or who underwent percutaneous coronary intervention to a vein graft, or died. Secondary outcomes included clinical outcomes and leg wound complications. Results: A total of 902 patients were enrolled with a mean total number of distal vein anastomoses of 2.0 (SD 0.87). The primary endpoint occurred in 90/454 (19.8%) of patients randomized to no-touch and in 107/446 (24.0%) of patients randomized to the conventional technique [difference, −4.3 percentage points; 95% confidence interval (CI) −10.1–1.6; P = .15] at a mean follow-up time of 3.5 (SD 0.1) years. The composite of death, myocardial infarction, or repeat revascularization at 4.4 (SD 1.3) years occurred in 57/454 (12.6%) and 44/446 (9.9%) in the no-touch and conventional groups, respectively (hazard ratio 1.3; 95% CI, 0.87–1.93). Leg wound complications were more common in patients assigned to no-touch harvesting at 3 months [107/433 (24.7%) vs. 59/427 (13.8%); difference, 10.9 percentage points; 95% CI 5.7–16.1]. At 2 years, 189/381 (49.6%) vs. 91/361 (25.2%) had remaining leg symptoms (difference, 24.4 percentage points; 95% CI 17.7–31.1). Conclusions: No-touch vein graft harvesting for CABG was not superior to conventional open harvesting in reducing vein graft failure or clinical events after CABG but increased leg wound complications. The primary outcome requires cautious interpretation due to a lower-than-expected number of primary events.
- Open Access
- 16 December 2024
- Published by Elsevier in American Journal of Infection Control
- Vol. 53 (4) , 467-472
Bacterial air contamination and the protective effect of coverage for sterile surgical goods: A randomized controlled trial
- 16 December 2024
- Published by Elsevier in American Journal of Infection Control
- Vol. 53 (4) , 467-472
Open AccessBacterial air contamination and the protective effect of coverage for sterile surgical goods: A randomized controlled trial
- 26 May 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (3)
The effect of postoperative atrial fibrillation on outcomes of cardiac surgery: guilt or association?
In this issue of the EJCTS, Oraii et al. present the results of a retrospective study on the effect of postoperative atrial fibrillation (POAF) on outcomes after CABG [ 1]. New-onset POAF was associated with an increased risk of mid-term mortality and stroke. However, in patients who survived an event-free early postoperative period, the late stroke risk was similar between patients with and without POAF, but late mortality was still higher in patients with POAF. The group from Tehran has conducted a thorough and comprehensive study. Their cohort was large, 2 different statistical methods, including 1 propensity score-based method, were applied to adjust for potential bias and both arrived—not surprisingly—at the same result. The result, however, raises many questions, and especially so when put in its context and compared with other recent publications with a similar study design. In 1 recent study, POAF was correlated to stroke but...
- 26 May 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (3)
The effect of postoperative atrial fibrillation on outcomes of cardiac surgery: guilt or association?
In this issue of the EJCTS, Oraii et al. present the results of a retrospective study on the effect of postoperative atrial fibrillation (POAF) on outcomes after CABG [ 1]. New-onset POAF was associated with an increased risk of mid-term mortality and stroke. However, in patients who survived an event-free early postoperative period, the late stroke risk was similar between patients with and without POAF, but late mortality was still higher in patients with POAF. The group from Tehran has conducted a thorough and comprehensive study. Their cohort was large, 2 different statistical methods, including 1 propensity score-based method, were applied to adjust for potential bias and both arrived—not surprisingly—at the same result. The result, however, raises many questions, and especially so when put in its context and compared with other recent publications with a similar study design. In 1 recent study, POAF was correlated to stroke but...
- Open Access
- 9 May 2022
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (5) , e1003997
Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial
Background: Animal and human data suggest that glutamate can enhance recovery of myocardial metabolism and function after ischemia. N-terminal pro-brain natriuretic peptide (NT-proBNP) reflects myocardial dysfunction after coronary artery bypass surgery (CABG). We investigated whether glutamate infusion can reduce rises of NT-proBNP in moderate- to high-risk patients after CABG. Methods and findings: A prospective, randomized, double-blind study enrolled patients from November 15, 2015 to September 30, 2020, with a 30-day follow-up at 4 academic cardiac surgery centers in Sweden. Patients underwent CABG ± valve procedure and had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h started 10 to 20 minutes before releasing the aortic cross-clamp, then continued for another 150 minutes. Patients, staff, and investigators were blinded to the treatment. The primary endpoint was the difference between preoperative and day-3 postoperative NT-proBNP levels. Analysis was intention to treat. We studied 303 patients (age 74 ± 7 years; females 26%, diabetes 47%), 148 receiving glutamate group and 155 controls. There was no significant difference in the primary endpoint associated with glutamate administration (5,390 ± 5,396 ng/L versus 6,452 ± 5,215 ng/L; p = 0.086). One patient died ≤30 days in the glutamate group compared to 6 controls (0.7% versus 3.9%; p = 0.12). No adverse events linked to glutamate were observed. A significant interaction between glutamate and diabetes was found (p = 0.03). Among patients without diabetes the primary endpoint (mean 4,503 ± 4,846 ng/L versus 6,824 ± 5,671 ng/L; p = 0.007), and the incidence of acute kidney injury (11% versus 29%; p = 0.005) was reduced in the glutamate group. These associations remained significant after adjusting for differences in baseline data. The main limitations of the study are: (i) it relies on a surrogate marker for heart failure; and (ii) the proportion of patients with diabetes had almost doubled compared to the cohort used for the sample size estimation. Conclusions: Infusion of glutamate did not significantly reduce postoperative rises of NT-proBNP. Diverging results in patients with and without diabetes agree with previous observations and suggest that the concept of enhancing postischemic myocardial recovery with glutamate merits further evaluation. Trial registration: ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02592824. European Union Drug Regulating Authorities Clinical Trials Database (Eudra CT number 2011-006241-15).
- 9 May 2022
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (5) , e1003997
Open AccessEffect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial
Background: Animal and human data suggest that glutamate can enhance recovery of myocardial metabolism and function after ischemia. N-terminal pro-brain natriuretic peptide (NT-proBNP) reflects myocardial dysfunction after coronary artery bypass surgery (CABG). We investigated whether glutamate infusion can reduce rises of NT-proBNP in moderate- to high-risk patients after CABG. Methods and findings: A prospective, randomized, double-blind study enrolled patients from November 15, 2015 to September 30, 2020, with a 30-day follow-up at 4 academic cardiac surgery centers in Sweden. Patients underwent CABG ± valve procedure and had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h started 10 to 20 minutes before releasing the aortic cross-clamp, then continued for another 150 minutes. Patients, staff, and investigators were blinded to the treatment. The primary endpoint was the difference between preoperative and day-3 postoperative NT-proBNP levels. Analysis was intention to treat. We studied 303 patients (age 74 ± 7 years; females 26%, diabetes 47%), 148 receiving glutamate group and 155 controls. There was no significant difference in the primary endpoint associated with glutamate administration (5,390 ± 5,396 ng/L versus 6,452 ± 5,215 ng/L; p = 0.086). One patient died ≤30 days in the glutamate group compared to 6 controls (0.7% versus 3.9%; p = 0.12). No adverse events linked to glutamate were observed. A significant interaction between glutamate and diabetes was found (p = 0.03). Among patients without diabetes the primary endpoint (mean 4,503 ± 4,846 ng/L versus 6,824 ± 5,671 ng/L; p = 0.007), and the incidence of acute kidney injury (11% versus 29%; p = 0.005) was reduced in the glutamate group. These associations remained significant after adjusting for differences in baseline data. The main limitations of the study are: (i) it relies on a surrogate marker for heart failure; and (ii) the proportion of patients with diabetes had almost doubled compared to the cohort used for the sample size estimation. Conclusions: Infusion of glutamate did not significantly reduce postoperative rises of NT-proBNP. Diverging results in patients with and without diabetes agree with previous observations and suggest that the concept of enhancing postischemic myocardial recovery with glutamate merits further evaluation. Trial registration: ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02592824. European Union Drug Regulating Authorities Clinical Trials Database (Eudra CT number 2011-006241-15).
- 29 November 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (5) , 1142-1143
The power of randomized controlled trials
The best way to treat postoperative sternal wound infection (SWI) after a median sternotomy is the object of many opinions. Treatment with revision, primary closure and often an irrigation-suction system used to be a common method and could be considered ‘conventional’. However, vacuum-assisted closure, also known as negative wound pressure therapy, has been strongly advocated by many. For several years, it has been the recommended and preferred treatment, at least in complicated cases [ 1, 2]. However, obviously, not all cardiac surgeons are convinced. A number of variations of the conventional method still exist, indisputably with very acceptable published results [ 3]. Surely many roads may lead to Rome, and different treatments might work equally well, depending on local experience and patient selection. Nevertheless, it is unsatisfactory that the scientific level of evidence behind all these different methods, with few exceptions, is limited to published single-centre experiences...
- 29 November 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (5) , 1142-1143
The power of randomized controlled trials
The best way to treat postoperative sternal wound infection (SWI) after a median sternotomy is the object of many opinions. Treatment with revision, primary closure and often an irrigation-suction system used to be a common method and could be considered ‘conventional’. However, vacuum-assisted closure, also known as negative wound pressure therapy, has been strongly advocated by many. For several years, it has been the recommended and preferred treatment, at least in complicated cases [ 1, 2]. However, obviously, not all cardiac surgeons are convinced. A number of variations of the conventional method still exist, indisputably with very acceptable published results [ 3]. Surely many roads may lead to Rome, and different treatments might work equally well, depending on local experience and patient selection. Nevertheless, it is unsatisfactory that the scientific level of evidence behind all these different methods, with few exceptions, is limited to published single-centre experiences...